NGNE.US Neurogene Inc

Healthcare Biotechnology USA Stocks
23.93 USD
Close of Nov 15, 2026
15.93 43.66
Market cap
USD 495M
P/E
-
P/B
1.40x
ROE
-35.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NGNE.US undervalued?

Graham number

The Graham number of Neurogene Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neurogene Inc fundamental analysis

No fundamental analysis for Neurogene Inc yet.

Neurogene Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neurogene Inc

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., …

Full company profile